Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies

EJNMMI Research

Table 1 Response among patients with advanced malignancies treated with sunitinib 50 mg/day on schedule 4/2

Patient	Primary tumour type	Reference tumour site	Change in perfusion at week 2 (%)	Change in FDG-SUV in reference tumour at week 2 (%)	Overall FDG-PET response at week 4	Radiological response in reference lesion at week 12	Overall radiological response at week 12	Duration of treatment (number of 6-week cycles)	Clinical benefit
1	Renal	Right hepatic lobe	−85	−39	Yes	SD	SD	4	Yes
2	Colon	Right hepatic lesion	−77	−37	Yes	SD	SD	6	Yes
3	Colon	Right hepatic lobe	−59	−33	Yes	PD	PD	2	No
4	Colon	Right hepatic lobe	−34	−44	Yes	PD	PD	2	No
5	NSCLC	Left lung lesion	−69	−67	Yes	SD	SD	12	Yes
6	Colon	Right hepatic lesion	−38	−32	Yes	SD	SD	7	Yes
7	Oesophageal	Right hepatic dome	−20	−29	No	PD	PD	2	No

Biological (week 2) and radiological (week 12) responses among patients with advanced malignancies treated with sunitinib 50 mg given once daily for 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2). Clinical benefit was deemed to be present if the treating clinician judged that the patient was benefiting from treatment and continued therapy beyond the 12-week study period. D15:D1, day15:day1 ratio; FDG-PET, ¹⁸ F-fluorodeoxyglucose positron emission tomography; FDG-SUV, ¹⁸ F-fluorodeoxyglucose standard uptake value; NSCLC, non-small cell lung cancer; PD, progressive disease; SD, stable disease.